All In MedTech

FDA Clearance Tracker · DEN140004

QUIDEL MOLECULAR DIRECT HSV 1 +2/VZV ASSAY

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 19, 2026Latest source record: May 13, 2014 (this decision)Source: openFDAMethods & limitations

De NovoNew device type

Decided

May 13, 2014

De Novo granted

Time to decision

81 days

Received Feb 21, 2014. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Post-NSE

Device class

Class II

The decision

FDA number
DEN140004
Device name
QUIDEL MOLECULAR DIRECT HSV 1 +2/VZV ASSAY
Applicant location
Athens, OH
Received
Feb 21, 2014
Decided
May 13, 2014
Decision
De Novo granted
Submission type
Post-NSE

Device type

Device class
Class II
Regulation
21 CFR 866.3309

Every decision under product code PGI

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Diagnostic Hybrids, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.